Moleculin Biotech Inc (MBRX NASDAQ) stock market data APIs
$0.3132
-0.01(-3.2%)
as of June 27, 2025
Try our APIs with
free plan!
Moleculin Biotech Inc Financial Data Overview
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Prev. Close
0.3132
Open
0.3055
High
0.3263
Low
0.2934
52 wk Range
0.25-4.707
Market Cap
4 411 K
Shares Outstanding
14 128 K
EPS
-0.69
Beta
1.565
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Moleculin Biotech Inc data using free add-ons & libraries
Get Moleculin Biotech Inc Fundamental Data
Moleculin Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -25 782 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.555
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Moleculin Biotech Inc News
New
Moleculin Biotech prices 16.08M shares at 37c in public offering
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a ...
Moleculin Biotech prices $5.9M public offering; shares down about 47%
* Moleculin Biotech (NASDAQ:MBRX [https://seekingalpha.com/symbol/MBRX]) is offering 16.08M shares or pre-funded warrants and Series E warrants to purchase up to 48.24M shares at $0.37/unit. * Ser...
Moleculin Announces $5.9 Million Public Offering
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidat...
Moleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AML
(RTTNews) - Moleculin Biotech, Inc. (MBRX) Wednesday said it has received positive feedback from U.S. Food and Drug Administration (FDA) regarding the company's initial pediatric study plan for Annamy...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
